| 中文名稱 | 細胞角蛋白5抗體 |
| 別 名 | Cytokeratin 5; Keratin, type II cytoskeletal 5; CK-5; CK 5; CK5; Keratin-5; K5; 58 kDa cytokeratin; KRT5; DDD; EBS 2; EBS2; K5; Keratin 5 (epidermolysis bullosa simplex Dowling-Meara/Kobner/Weber-Cockayne types); Keratin 5; Keratin Type II Cytoskeletal 5; Keratin5; KRT 5; KRT 5A; KRT5; Cytokeratin-5; Cytokeratin5; DDD; epidermolysis bullosa simplex 2 Dowling-Meara/Kobner/Weber-Cockayne types; K2C5_HUMAN; Keratin 5; Keratin; Keratin Type II Cytoskeletal 5; Keratin5; KRT5A; type II cytoskeletal 5; Type-II keratin Kb5. |
| 研究領域 | 腫瘤 信號轉導 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | Human, Mouse, Rat, (predicted: Dog, Pig, Cow, Horse, Rabbit, ) |
| 產品應用 | WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=1μg/Test IF=1:100-500 （石蠟切片需做抗原修復） not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 64kDa |
| 細胞定位 | 細胞核 細胞漿 細胞外基質 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human CK5:331-430/590 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. |
| PubMed | PubMed |
| 產品介紹 | Cytokeratins (CK) are intermediate filaments of epithelial cells, both in keratinising tissue (ie., skin) and non keratinising cells (ie., mesothelial cells). Although not a traditional marker for endothelial cells, cytokeratins have also been found in some microvascular endothelial cells. At least 20 different cytokeratins (CK) in the molecular range of 40 to 70 kDa and isoelectric points of 5 to 8.5 can be identified using two dimensional gel electrophoresis. Biochemically, most members of the CK family fall into one of two classes, type I (acidic polypeptides) and type II (basic polypeptides). At least one member of the acidic family and one member of the basic family is expressed in all epithelial cells. Defects in KRT5 are a cause of epidermolysis bullosa simplex. Subunit: Heterotetramer of two type I and two type II keratins. Keratin-5 associates with keratin-14. Interacts with TCHP. DISEASE: Defects in KRT5 are a cause of epidermolysis bullosa simplex Dowling-Meara type (DM-EBS) [MIM:131760]. DM-EBS is a severe form of intraepidermal epidermolysis bullosa characterized by generalized herpetiform blistering, milia formation, dystrophic nails, and mucous membrane involvement. Defects in KRT5 are the cause of epidermolysis bullosa simplex with migratory circinate erythema (EBSMCE) [MIM:609352]. EBSMCE is a form of intraepidermal epidermolysis bullosa characterized by unusual migratory circinate erythema. Skin lesions appear from birth primarily on the hands, feet, and legs but spare nails, ocular epithelia and mucosae. Lesions heal with brown pigmentation but no scarring. Electron microscopy findings are distinct from those seen in the DM-EBS, with no evidence of tonofilament clumping. Defects in KRT5 are a cause of epidermolysis bullosa simplex Weber-Cockayne type (WC-EBS) [MIM:131800]. WC-EBS is a form of intraepidermal epidermolysis bullosa characterized by blistering limited to palmar and plantar areas of the skin. Defects in KRT5 are a cause of epidermolysis bullosa simplex Koebner type (K-EBS) [MIM:131900]. K-EBS is a form of intraepidermal epidermolysis bullosa characterized by generalized skin blistering. The phenotype is not fundamentally distinct from the Dowling-Meara type, althought it is less severe. Defects in KRT5 are the cause of epidermolysis bullosa simplex with mottled pigmentation (MP-EBS) [MIM:131960]. MP-EBS is a form of intraepidermal epidermolysis bullosa characterized by blistering at acral sites and 'mottled' pigmentation of the trunk and proximal extremities with hyper- and hypopigmentation macules. Defects in KRT5 are the cause of Dowling-Degos disease (DDD) [MIM:179850]; also known as Dowling-Degos-Kitamura disease or reticulate acropigmentation of Kitamura. DDD is an autosomal dominant genodermatosis. Affected individuals develop a postpubertal reticulate hyperpigmentation that is progressive and disfiguring, and small hyperkeratotic dark brown papules that affect mainly the flexures and great skin folds. Patients usually show no abnormalities of the hair or nails. Similarity: Belongs to the intermediate filament family. SWISS: P13647 Gene ID: 3852 Database links: Entrez Gene: 3852 Human Entrez Gene: 110308 Mouse Entrez Gene: 369017 Rat Omim: 148040 Human SwissProt: P13647 Human SwissProt: Q922U2 Mouse SwissProt: Q6P6Q2 Rat Unigene: 433845 Human Unigene: 451847 Mouse Unigene: 129725 Rat Unigene: 195318 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 結構蛋白（Structural Proteins） 細胞角蛋白5，為高分子量細胞角蛋白 58 kDa ，表達在皮膚的基底細胞和棘層細胞，部分前列腺基底細胞，與其它單層腺上皮不表達。主要用于間皮瘤與腺癌的鑒別診斷。 細胞角蛋白是一類與結構相關的蛋白家族，其在上皮細胞中形成細胞骨架中間絲。CK5是在表皮角質化細胞中大量表達的4種角蛋白之一。CK5可用以區分正常細胞和腫瘤細胞。在基底細胞上皮瘤、多種鱗狀細胞癌（皮膚和舌）、多種上皮細胞和間皮瘤都有CK5的表達。 |
| 產品圖片 |  Sample:Lane 1: Skin (Mouse) Lysate at 40 ug Lane 2: Uterus (Mouse) Lysate at 40 ug Lane 3: Urinary bladder (Mouse) Lysate at 40 ug Lane 4: Esophagus (Mouse) Lysate at 40 ug Lane 5: Skin (Rat) Lysate at 40 ug Lane 6: Uterus (Rat) Lysate at 40 ug Lane 7: Urinary bladder (Rat) Lysate at 40 ug Lane 8: Esophagus (Rat) Lysate at 40 ug Primary: Anti-Cytokeratin 5 (bs-1060R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 62 kD Observed band size: 60 kD  Sample:Skin (Mouse) Lysate at 40 ug Primary: Anti-Cytokeratin 5 (bs-1060R) at 1/300 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 64 kD Observed band size: 64 kD  Sample:MDA-MB-231(Human) Cell Lysate at 40 ug MCF-7(Human) Cell Lysate at 40 ug Primary: Anti-Cytokeratin 5 (bs-1060R) at 1/300 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 64 kD Observed band size: 64 kD  Paraformaldehyde-fixed, paraffin embedded (human breast carcinoma); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Cytokeratin 5) Polyclonal Antibody, Unconjugated (bs-1060R) at 1:400 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining. Paraformaldehyde-fixed, paraffin embedded (human cervical cancer); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Cytokeratin 5) Polyclonal Antibody, Unconjugated (bs-1060R) at 1:400 overnight at 4°C, followed by a conjugated secondary (sp-0023) for 20 minutes and DAB staining. Paraformaldehyde-fixed, paraffin embedded (rat bladder tissue); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Cytokeratin 5) Polyclonal Antibody, Unconjugated (bs-1060R) at 1:400 overnight at 4°C, followed by a conjugated secondary (sp-0023) for 20 minutes and DAB staining. Blank control: Hela Cells(blue).Primary Antibody: Rabbit Anti-Cytokeratin 5/AF488 Conjugated antibody (bs-1060R/AF488), Dilution: 1μg in 100 μL 1X PBS containing 0.5% BSA; Isotype Control Antibody: Rabbit IgG/AF488 (orange) ,used under the same conditions. Protocol The cells were fixed with 2% paraformaldehyde (10 min) and then permeabilized with ice-cold 90% methanol for 30 min on ice. The cells were washed twice with 1 X PBS. The cells were incubated in 1 X PBS containing 0.5% BSA + 1 0% goat serum (15 min) to block non-specific protein-protein interactions followed by the incubated with antibody (bs-1060R/AF488, 1μg /1x10^6 cells) for 30 min on ice. Acquisition of 20,000 events was performed. |
我要詢價
*聯系方式：
(可以是QQ、MSN、電子郵箱、電話等，您的聯系方式不會被公開)
*內容：
